Share on StockTwits

Zeltiq Aesthetics (NASDAQ:ZLTQ) Director Kevin C. Oboyle sold 5,000 shares of Zeltiq Aesthetics stock on the open market in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $21.08, for a total value of $105,400.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

A number of analysts have recently weighed in on ZLTQ shares. Analysts at Leerink Swann raised their price target on shares of Zeltiq Aesthetics from $26.00 to $27.00 in a research note on Thursday. Separately, analysts at Maxim Group raised their price target on shares of Zeltiq Aesthetics from $25.00 to $30.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Cantor Fitzgerald reiterated a “positive” rating on shares of Zeltiq Aesthetics in a research note on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Zeltiq Aesthetics presently has an average rating of “Buy” and an average price target of $24.26.

Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) traded down 5.15% on Thursday, hitting $20.24. 1,857,808 shares of the company’s stock traded hands. Zeltiq Aesthetics has a one year low of $6.67 and a one year high of $24.79. The stock’s 50-day moving average is $15.94 and its 200-day moving average is $17.84. The company’s market cap is $757.8 million.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.20. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $34.93 million. The company’s quarterly revenue was up 79.1% on a year-over-year basis. On average, analysts predict that Zeltiq Aesthetics will post $-0.39 earnings per share for the current fiscal year.

Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.